Galectin Therapeutics(NASDAQ) GALT

Galectin Therapeutics Inc. helps people with liver disease. These drugs stop organ scarring and tumor growth. These medicines support patients with few other treatment options.

Targeting the Root of Disease

• Belapectin: Injectable drug candidate derived from plants that blocks specific proteins to treat liver scarring and tumors.
• Oral Inhibitors: Early-stage medications developed through a joint venture to block proteins using a pill instead of an injection.
• Combination Therapies: Research programs using the company’s lead drug alongside existing cancer medications to help the immune system fight tumors.

Progress Toward Clinical Success

• Reported top-line results from the NAVIGATE clinical trial in December 2024 for patients with liver cirrhosis.
• Reached an agreement with the FDA in the second quarter of 2026 on the regulatory path for potential drug approval.
• Received a Study May Proceed letter from the FDA in the third quarter of 2022 for a new trial in head and neck cancer.
• Formed Galectin Sciences LLC to develop alternative drug delivery methods, including medications that can be taken by mouth.

Natural Science Meets Modern Medicine

Galectin uses complex carbohydrates from natural plants as the starting material for its patented drug candidates. These compounds specifically target galectin-3, a protein that acts like molecular glue in the development of many life-threatening diseases.

Measuring Financial Progress

• Research and development expenses were $4.4 million for the six-month period ended June 30, 2026, down 55% year over year.
• General and administrative expenses were $3.7 million for the six-month period ended June 30, 2026, up 33% year over year.
• Unrestricted cash and cash equivalents totaled $13.3 million as of June 30, 2026.
• Total net proceeds raised from debt and equity offerings reached $342 million as of June 30, 2026.

Evolution of Galectin

Galectin has transitioned from early research to late-stage clinical trials focused on high-need liver and cancer conditions. The company's future depends on securing strategic partnerships or new funding to complete its final development phases.